A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)

Phase 1 Completed 8 enrolled Merck Sharp & Dohme LLC

NaSingle-groupOpen-labelBasic science

Summary

The goal of this study is to understand how radiolabeled MK-5475 administered intravenously (IV) is taken up by the body, broken down and then removed from the body in healthy male participants. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.

Timeline

Start: 2022-08-15
Primary completion: 2022-09-30
Completion: 2022-10-25

Publications

Results Menzel K, Liang Y, Chen B, Li D, Cislak D, Bajwa EK. An Intravenous Study with the Radiolabeled sGC Stimulator Frespaciguat to Assess PK, Metabolism, and Mass Balance. J Clin Pharmacol. 2025 Nov;65(11):1561-1567. doi: 10.1002/jcph.70066. Epub 2025 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Frespaciguat	Small molecule	100 ug	Intravenous

Indications

No indication recorded.